DC Field | Value | Language |
---|---|---|
dc.contributor.author | OKOLICANY, J | ko |
dc.contributor.author | MCENROE, GA | ko |
dc.contributor.author | Koh, Gou Young | ko |
dc.contributor.author | LEWICKI, JA | ko |
dc.contributor.author | MAACK, T | ko |
dc.date.accessioned | 2013-02-27T07:31:59Z | - |
dc.date.available | 2013-02-27T07:31:59Z | - |
dc.date.created | 2012-02-06 | - |
dc.date.created | 2012-02-06 | - |
dc.date.issued | 1992-09 | - |
dc.identifier.citation | AMERICAN JOURNAL OF PHYSIOLOGY, v.263, no.3, pp.553 - 2 | - |
dc.identifier.issn | 0002-9513 | - |
dc.identifier.uri | http://hdl.handle.net/10203/67270 | - |
dc.description.abstract | A novel small linear C-atrial natriuretic factor receptor ligand [C-ANF-(11-15)] and phosphoramidon (PHO) were used to determine the effects of C-ANF receptor blockade alone, or in combination with inhibition of neutral endopeptidase (NEP), on the pharmacokinetics and-metabolism of ANF in the rat. C-ANF-(11-15) infusion decreased apparent volume of distribution (V(ss)) and metabolic clearance rate (MCR) of administered I-125-ANF-(1-28) to one-third of their control values, whereas PHO alone was without effect on these parameters. In combination with C-ANF(11-15), however, PHO further decreased MCR of I-125-ANF(1-28) and increased plasma half time by more than threefold. High-performance liquid chromatography analysis revealed that C-ANF-(11-15) inhibited the delayed appearance of free I-125 and [I-125] monoiodotyrosine but had no effect on the small proportion of NEP metabolites in plasma. The combination of C-ANF-(11-15) and PHO further delayed the appearance of small metabolites, abolished the appearance of NEP metabolites, and markedly prolonged the permanence of intact I-125-ANF-(1-28) in plasma. The results demonstrate that C-ANF receptor blockade by C-ANF-(11-15) impairs clearance and metabolism of ANF, an effect which is synergistically potentiated by concomitant inhibition of NEP. C-ANF-(11-15) alone or in combination with NEP inhibitors may be a potentially useful therapeutic tool in the treatment of cardiovascular and renal diseases. | - |
dc.language | English | - |
dc.publisher | AMER PHYSIOLOGICAL SOC | - |
dc.subject | CYCLIC-GMP ACCUMULATION | - |
dc.subject | PEPTIDE ANALOGS | - |
dc.subject | INHIBITOR | - |
dc.subject | MEMBRANES | - |
dc.subject | BINDING | - |
dc.subject | KIDNEY | - |
dc.subject | DEGRADATION | - |
dc.subject | STIMULATION | - |
dc.subject | EXPRESSION | - |
dc.subject | HYDROLYSIS | - |
dc.title | CLEARANCE RECEPTOR AND NEUTRAL ENDOPEPTIDASE-MEDIATED METABOLISM OF ATRIAL-NATRIURETIC-FACTOR | - |
dc.type | Article | - |
dc.identifier.wosid | A1992JP90200119 | - |
dc.identifier.scopusid | 2-s2.0-0026665240 | - |
dc.type.rims | ART | - |
dc.citation.volume | 263 | - |
dc.citation.issue | 3 | - |
dc.citation.beginningpage | 553 | - |
dc.citation.endingpage | 2 | - |
dc.citation.publicationname | AMERICAN JOURNAL OF PHYSIOLOGY | - |
dc.contributor.localauthor | Koh, Gou Young | - |
dc.contributor.nonIdAuthor | OKOLICANY, J | - |
dc.contributor.nonIdAuthor | MCENROE, GA | - |
dc.contributor.nonIdAuthor | LEWICKI, JA | - |
dc.contributor.nonIdAuthor | MAACK, T | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | CLEARANCE ATRIAL NATRIURETIC FACTOR RECEPTOR | - |
dc.subject.keywordAuthor | CLEARANCE ATRIAL NATRIURETIC FACTOR-(11-15) | - |
dc.subject.keywordAuthor | PHOSPHORAMIDON | - |
dc.subject.keywordAuthor | CLEARANCE | - |
dc.subject.keywordAuthor | HYDROLYSIS | - |
dc.subject.keywordAuthor | RAT | - |
dc.subject.keywordAuthor | PHARMACOKINETICS | - |
dc.subject.keywordPlus | CYCLIC-GMP ACCUMULATION | - |
dc.subject.keywordPlus | PEPTIDE ANALOGS | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | MEMBRANES | - |
dc.subject.keywordPlus | BINDING | - |
dc.subject.keywordPlus | KIDNEY | - |
dc.subject.keywordPlus | DEGRADATION | - |
dc.subject.keywordPlus | STIMULATION | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | HYDROLYSIS | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.